Skip to main content

molnupiravir

Generic: molnupiravir·Brand: Lagevrio

molnupiravir: 3 clinical trials tracked.

molnupiravir evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about molnupiravir, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (3)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression

NCT06667700·Phase 3
Recruiting

Primary endpoint: Percentage of Participants Who Experienced One or More of Following Through Day 29: All-cause Hospitalization, All-cause Mortality, or Covid-19-related Medically-attended Visit (MAV)

InterventionalRandomizeddouble3,082 targetStarted 2024-12Completion 2031-0150 sites · United StatesMerck Sharp & Dohme LLC

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

NCT05041907·Phase 2·ENTA
Recruiting

Primary endpoint: Rate of viral clearance for interventions relative to the no study arm (This is a superiority comparison)

InterventionalRandomizedopen3,800 targetStarted 2021-09Completion 2027-017 sites · Brazil, Laos, Nepal, Pakistan…University of Oxford

Randomised Evaluation of COVID-19 Therapy

NCT04381936·Phase 3
Recruiting

Primary endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)

InterventionalRandomizedopen70,000 targetStarted 2020-03Completion 2038-0916 sites · Belgium, Estonia, France, Ghana…University of Oxford